European Journal of Surgical Oncology
Volume 36, Issue 5 , Pages 463-469 , May 2010

Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

  • D. Baratti

      Affiliations

    • Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    • ,
  • A. Scivales

      Affiliations

    • Medtronic Italia, Piazza Montanelli, 30, 20099 Sesto San Giovanni (MI), Italy
    • ,
  • M.R. Balestra

      Affiliations

    • Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    • ,
  • P. Ponzi

      Affiliations

    • Medtronic Italia, Piazza Montanelli, 30, 20099 Sesto San Giovanni (MI), Italy
    • ,
  • F. Di Stasi

      Affiliations

    • Medtronic Italia, Piazza Montanelli, 30, 20099 Sesto San Giovanni (MI), Italy
    • ,
  • S. Kusamura

      Affiliations

    • Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    • ,
  • B. Laterza

      Affiliations

    • Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    • ,
  • M. Deraco

      Affiliations

    • Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 23902362; fax: +39 02 23902404.

,Accepted 15 March 2010.

References 

  1. Sugarbaker PH. Progress in the management of carcinomatosis. Cancer J. 2009;15:182–183
  2. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42
  3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasm with pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;1:69–76
  4. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–6242
  5. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a Multicentric French study. J Clin Oncol. 2010;28:63–68
  6. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18:1943–1950
  7. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. The Lancet. 2009;374:1371–1382
  8. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:77–79
  9. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53
  10. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32:671–675
  11. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243–249
  12. Oken MM, Creech RH, Tormey , et al. Toxicity and response criteria of the Eastern Cooperative Oncology group. Am J Clin Oncol. 1982;5:649–655
  13. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–328
  14. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58
  15. Fujimoto S, Takahashi M, Kobayashi K, et al. Combined treatment of pelvic exenterative surgery and intraoperative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today. 1993;23:1094–1098
  16. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer. 2002;94:492–499
  17. Ramsey RH. Activity-based costing for hospitals. Hosp Health Serv Adm. 1994;39:385–396
  18. Khatri VP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient?. J Clin Oncol. 2010;28:5–7
  19. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2003;21:37–43
  20. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685
  21. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–907
  22. Bonastre J, Chevalier J, Elias D, et al. Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer. Value Health. 2008;11:347–353
  23. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9:1–142
  24. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22:854–863
  25. Bonastre J, Jan P, de Pouvourville G, Pocard M, Estphan G, Elias D. [Cost of an intraperitoneal chemohyperthermia (IPCH) related to cytoreductive surgery]. Ann Chir. 2005;130:553–561
  26. Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol. 2006;32:614–618
  27. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–280
  28. Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005;92:153–158
  29. Chua TC, Martin S, Saxena A, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg. 2010;251:323–329
  30. Chann YC. Improving hospital cost accounting with activity-based costing. Health Care Manage Rev. 1993;18:71–77

PII: S0748-7983(10)00061-2

doi: 10.1016/j.ejso.2010.03.005

European Journal of Surgical Oncology
Volume 36, Issue 5 , Pages 463-469 , May 2010

Article Tools